Kangen Pharmaceuticals announced Wednesday it has reached an agreement to acquire the assets of KC Specialty Therapeutics (KCST). Kangen intends to retain operations in Kansas City, Kansas and expand within Japan and the U.S. KCST has an existing portfolio of products focused on niche indications, and orphan drug designations. This acquisition also creates for Kangen an expanded network of affiliates and alliances…